- About Us
- Sam Clubs
- Sam Mall
- Contact Us
Dr. Urmi Ashar is the President & CEO of Advanced Technology Healthcare Solutions, a bio-analytics company specializing in genomics based human drug interaction testing and analysis. The company is a leader in the field of personalized Rx profiles. Dr. Ashar is a internationally recognized thought leader who uses insights derived from the study of medicine, science, education and business as well as from the experience of bridging two cultures – American and Indian – to build simple, non-conventional solutions to complex life science challenges. She has successfully started and sold two businesses in Mumbai, India while leading a clinical practice in Anesthesiology and is the founder of National Association of Corporate Directors Three Rivers Chapter. Dr. Ashar is actively engaged at the grassroots level with communities in Pittsburgh and Mumbai, India. She currently serves on the board of Excela Health, NACD Three Rivers and The Abundant Health Community.
Dr. Ashar earned her MBA from the University of Colorado and attained a diploma in Entrepreneurship for Life Sciences Technology from UPMC. She earned her MBBS (Bachelor of Medicine and Bachelor of Surgery) and MD from KEM Hospital and the University of Mumbai’s Seth G.S. Medical College. She is a Diplomate of the National Board in Anesthesiology (India).
Advanced Technology Healthcare Solutions (ATHS) is a bioinformatics company that focuses on reducing adverse drug reactions and improving prescription drug effectiveness for patients aged 50 & older and children aged 18 & under. Results from ATHS’s individual genetic test are combined with the most current biomedical information to produce an actionable personalized report called MySafeMedsTM Physicians and consumers use the insights from this report to personalize their prescriptions to help improve outcomes from treatment. Adverse Drug Reactions are now the fourth leading cause of death in the United States and cost our health care system $177 Billion each year. Also, research has shown that medication ineffectiveness can range from 38% to as high as 75% for certain drug and disease categories based on an individuals genetic make-up. The potential market opportunity for ATHS’s MySafeMedsTM is $3 billion. The overall market opportunity for pharmacogenetic testing, in general, is projected to grow to over $25 billion by 2021, fueled by a push towards personalized healthcare.